Qiagen N.V. $QGEN Position Raised by Perbak Capital Partners LLP

Perbak Capital Partners LLP boosted its position in Qiagen N.V. (NYSE:QGEN) by 78.2% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 104,838 shares of the company’s stock after purchasing an additional 46,002 shares during the period. Qiagen makes up about 0.8% of Perbak Capital Partners LLP’s portfolio, making the stock its 13th largest holding. Perbak Capital Partners LLP’s holdings in Qiagen were worth $4,684,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Smartleaf Asset Management LLC increased its position in shares of Qiagen by 1,383.3% during the 3rd quarter. Smartleaf Asset Management LLC now owns 890 shares of the company’s stock valued at $39,000 after purchasing an additional 830 shares during the period. MAI Capital Management raised its stake in shares of Qiagen by 998.9% in the 2nd quarter. MAI Capital Management now owns 978 shares of the company’s stock worth $47,000 after buying an additional 889 shares in the last quarter. Allworth Financial LP lifted its holdings in shares of Qiagen by 260.1% in the second quarter. Allworth Financial LP now owns 1,102 shares of the company’s stock valued at $53,000 after buying an additional 796 shares during the period. GAMMA Investing LLC lifted its holdings in shares of Qiagen by 375.5% in the third quarter. GAMMA Investing LLC now owns 1,241 shares of the company’s stock valued at $55,000 after buying an additional 980 shares during the period. Finally, Jones Financial Companies Lllp boosted its stake in Qiagen by 64.0% during the third quarter. Jones Financial Companies Lllp now owns 1,610 shares of the company’s stock valued at $71,000 after buying an additional 628 shares in the last quarter. 70.00% of the stock is owned by institutional investors.

Qiagen Price Performance

QGEN opened at $40.59 on Friday. The firm has a market capitalization of $8.57 billion, a P/E ratio of 20.13, a PEG ratio of 2.01 and a beta of 0.70. The stock has a fifty day moving average of $49.32 and a 200-day moving average of $48.86. The company has a quick ratio of 3.31, a current ratio of 3.90 and a debt-to-equity ratio of 0.44. Qiagen N.V. has a 12-month low of $40.14 and a 12-month high of $57.81.

Qiagen (NYSE:QGEN) last issued its quarterly earnings results on Thursday, February 5th. The company reported $0.62 earnings per share for the quarter, beating analysts’ consensus estimates of $0.61 by $0.01. The business had revenue of $540.42 million for the quarter, compared to the consensus estimate of $528.53 million. Qiagen had a return on equity of 14.56% and a net margin of 20.33%.Qiagen’s revenue for the quarter was up 3.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.61 earnings per share. Equities analysts forecast that Qiagen N.V. will post 2.26 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts recently issued reports on QGEN shares. Barclays set a $58.00 target price on Qiagen and gave the stock an “overweight” rating in a report on Friday, February 6th. Deutsche Bank Aktiengesellschaft upgraded shares of Qiagen from a “hold” rating to a “buy” rating and set a $54.00 price objective for the company in a research report on Friday. TD Cowen reaffirmed a “hold” rating on shares of Qiagen in a research note on Friday, February 6th. Jefferies Financial Group reiterated a “buy” rating and issued a $59.00 target price on shares of Qiagen in a report on Thursday, February 5th. Finally, Citigroup cut their target price on shares of Qiagen from $55.40 to $55.00 and set a “neutral” rating for the company in a research note on Friday, February 6th. Five research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $55.20.

About Qiagen

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.